Oncology

Your Article Summary

See Latest Articles

Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: A meta-analysis involving 46,281 subjects
Breast Cancer Research and Treatment, 11/30/09

Qiu LX et al. – This meta-analysis suggests that the GSTM1 null genotype is a low-penetrant risk factor for developing breast cancer.

• Meta-analysis
• Medline, PubMed, Embase, and Web of Science searched
• Crude ORs with 95% CIs used to assess strength of association between GSTM1 present/null polymorphism and breast cancer risk
• Total of 59 studies including 20,993 cases and 25,288 controls involved

• Significantly elevated breast cancer risk associated with null genotype when all studies were pooled into meta-analysis (OR = 1.10, 95% CI = 1.04–1.16)
• In subgroup analysis by ethnicity, significantly increased risks found for Caucasians (OR = 1.05, 95% CI = 1.00–1.10) and Asians (OR = 1.21, 95% CI = 1.08–1.35)
• When stratified by population-based studies or hospital-based studies, statistically significantly elevated risks found among population-based studies (OR = 1.11, 95% CI = 1.03–1.20)
• In subgroup analysis by menopausal status, statistically significantly increased risks found among postmenopausal women (OR = 1.15, 95% CI = 1.04–1.28)

Today in Basic Science/Genetics...keeping you current

Receive free subspecialty "5-minute updates" via email

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
BMC Cancer, 02/09/10

TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer
Genes, Chromosomes and Cancer, 02/09/10

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
Cancer Chemotherapy and Pharmacology, 02/09/10

 See all of Basic Science/Genetics

Today in Breast...keeping you current

Receive free subspecialty "5-minute updates" via email

Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): A phase II randomised trial
The Lancet Oncology - Online First, 02/09/10

Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials
The Lancet Oncology - Online First, 02/09/10

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
BMC Cancer, 02/09/10

 See all of Breast